Helicobacter pylori as a risk factor for gastric cancer: the evidence and primary prevention strategy

• Published in: Alʹmanakh klinicheskoĭ medit͡s︡iny Vol. 47; no. 6; pp. 535 - 547
• Main Authors: Voynovan, I. N., Embutnieks, Yu. V., Mareeva, D. V., Kolbasnikov, S. V., Bordin, D. S.
• Format: Journal Article
• Language: English
• Published: MONIKI 22.12.2019
• Subjects: diagnostic methods; eradication; gastric cancer; gastric precancerous lesions; helicobacter pylori; risk factors
• ISSN: 2072-0505; 2587-9294
• DOI: 10.18786/2072-0505-2019-47-052

Russia is a country with a high prevalence of Helicobacter pylori (HP) infection, a high incidence of gastric cancer, and its late diagnosis. HР infection has been recognized as the leading manageable risk factor for gastric cancer. Accurate diagnostic tests must be used to identify and control the effectiveness of HP eradication, and effective schemes must be implemented for HP eradication. The aim of this article was to analyze the latest consensus documents, systematic reviews and meta-analyzes that reflected the role of HP as a risk factor for the development of gastric cancer, as well as measures for the risk reduction. We describe in detail the diagnostic methods for HP infection, provide data on their use in the Russian Federation, and analyze the efficacy of eradication regimens. In all HPinfected individuals, HP leads to chronic inflammation in the gastric mucosa and launches a precancerous cascade (Correa's cascade). The risk of gastric cancer increases with severe atrophy, intestinal metaplasia and dysplasia. Primary prevention of gastric cancer is most effective if the eradication is performed before atrophic gastritis develops. The available consensus documents underline the importance of HP infection identification by accurate diagnostics at this stage of chronic gastritis. In Russia, the primary HP diagnosis is based on histology (37.7%), rapid urease test (29.2%), and serology (29.7%). HP stool antigen test (31.3%), 13 C-urea breath test (23.4%) and the histological method (23.3%) are most often used to control eradication. Currently, the first line of eradication therapy is recommended as triple therapy with clarithromycin prescribed for 14 days. It is recommended to use double dose of proton pump inhibitors and bismuth to increase the effectiveness of this scheme. A 14-days triple regimen enhanced by bismuth has been recommended as the first-line therapy in the Russian Federation.